Akzo Nobel NV
F:AKUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Akzo Nobel NV
F:AKUP
|
NL |
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
US |
|
Industrial and Commercial Bank of China Ltd
F:ICKB
|
CN |
|
Computacenter PLC
LSE:CCC
|
UK |
|
Amphastar Pharmaceuticals, Inc
NASDAQ:AMPH
|
US |
|
Petrolia S.E
OSE:PSE
|
CY |
|
Hipay Group SA
PAR:ALHYP
|
FR |
|
W
|
Westwater Resources Inc
F:UCCP
|
US |
|
Wheels Up Experience Inc
NYSE:UP
|
US |
|
WidePoint Corp
F:ZMX1
|
US |
|
Simplex Infrastructures Ltd
NSE:SIMPLEXINF
|
IN |
|
V
|
Volatus Aerospace Inc
SWB:ABB
|
CA |
|
B
|
BioMarin Pharmaceutical Inc
XMUN:BM8
|
US |
|
A
|
African Rainbow Minerals Ltd
XMUN:EB9
|
ZA |
|
A
|
Alphabet Inc
XHAM:ABEA
|
US |
|
Samsung Electronics Co Ltd
F:SSUN
|
KR |
Earnings Calls
Last Earnings Call
Growth and margins: AkzoNobel said Q2 delivered 2% organic sales growth, 3% pricing, flat volumes, and another quarter of year-over-year margin expansion.
Profitability: Adjusted EBITDA was EUR 398 million, up 5% at comparable scope, with adjusted EBITDA margin at 15.4% and adjusted gross margin at 42.7%.
Outlook unchanged: Management left its 2026 adjusted EBITDA target at or above EUR 1,470 million and guided Q3 adjusted EBITDA at around EUR 390 million.
Cost actions: The company said pricing is covering current inflation and that industrial savings, including EUR 90 million this year, remain the main driver of the full-year step-up.
Axalta deal: Merger preparations are on track, with the shareholder vote set for August 5 and management still aiming to close by the end of 2026 or early 2027.
Cash flow: Free cash flow was EUR 108 million in Q2, trade working capital improved, and full-year cash flow guidance was unchanged.
Portfolio and Russia: Management said its Deco portfolio strategy is unchanged, Southeast Asia remains under review, and the Russia business is not material to group guidance.